Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization. A Randomized Controlled Trial
Status: Recruiting
Location: See all (5) locations...
Intervention Type: Drug, Other
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
This is a randomized, controlled clinical trial with a two-sided superiority hypothesis. The study evaluates whether a 12-week pre-treatment with semaglutide prior to ovarian stimulation improves the number of good-quality blastocysts in overweight and obese women undergoing in vitro fertilization (IVF), compared to no pre-treatment.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 38
Healthy Volunteers: f
View:
• ≤ 38 years
• AMH \>= 1 ng/mL or AFC \>= 6
• Body mass index (BMI) between 27 kg/m2 and 40 kg/m2
• Scheduled for IVF with freeze-all strategy
Locations
Other Locations
Spain
Departamento de Ginecología Obstetricia y Reproducción. Hospital Universitari Dexeus
RECRUITING
Barcelona
Dexeus Mujer Reus
NOT_YET_RECRUITING
Reus
Dexeus Mujer Sabadell
NOT_YET_RECRUITING
Sabadell
Dexeus Mujer Sant Cugat
NOT_YET_RECRUITING
Sant Cugat Del Vallès
Dexeus Mujer Tarragona
NOT_YET_RECRUITING
Tarragona
Contact Information
Primary
Nikolaos P Polyzos, MD, PhD
nikpol@dexeus.com
0034932274700
Backup
Ignacio Rodríguez, MSc
nacrod@dexeus.com
0034932274700
Time Frame
Start Date: 2026-01-19
Estimated Completion Date: 2027-05
Participants
Target number of participants: 62
Treatments
Experimental: Semaglutide
Semaglutide 0.25-1.0 mg for 12 weeks prior to ovarian stimulation
Active_comparator: No pre-treatment
No pre-treatment prior to ovarian stimulation Pre-treatment
Related Therapeutic Areas
Sponsors
Leads: Fundacion Dexeus